Peng Guang-Cheng, Hao Jin-Hua, Guan Yue-Qin, Wang Ying-Yue, Liu Ming-Jie, Li Guo-Hui, Xu Zhen-Peng, Wen Xue-Sen, Shen Tao
Key Lab of Chemical Biology (MOE), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 Wenhua Xi Road, Jinan, 250012, People's Republic of China.
Jiuhua Huayuan Pharmaceutical Co., Ltd., Chuzhou, People's Republic of China.
Chin Med. 2024 May 8;19(1):67. doi: 10.1186/s13020-024-00940-y.
Thesium chinense Turcz. (Named as Bai Rui Cao in Chinese) and its preparations (e.g., Bairui Granules) have been used to treat inflammatory diseases, such as acute mastitis, lobar pneumonia, tonsillitis, coronavirus disease 2019 (COVID-19), and upper respiratory tract infection. However, the material basis, pharmacological efficiency, and safety have not been illustrated.
Anti-inflammatory activity-guided isolation of constituents has been performed using multiple column chromatography, and their structures were elucidated by NMR spectroscopy and ECD calculations. The inhibitory effects on lung inflammation and safety of the crude ethanol extract (CE), Bairui Granules (BG), and the purified active constituents were evaluated using lipopolysaccharide (LPS)-stimulated acute lung inflammation (ALI) mice model or normal mice.
Seven new compounds (1-7) and fifty-six known compounds (8-63) were isolated from T. chinense, and fifty-four were reported from this plant for the first time. The new flavonoid glycosides 1-2, new fatty acids 4-5, new alkaloid 7 as well as the known constituents including flavonoid aglycones 8-11, lignans 46-54, alkaloids 34 and 45, coumarins 57, phenylpropionic acids 27, and simple aromatic compounds 39, 44 and 58 exhibited anti-inflammatory activity. Network pharmacology analysis indicated that anti-inflammation of T. chinense was attributed to flavonoids and alkaloids by regulating inflammation-related proteins (e.g., TNF, NF-κB, TGF-β). Furthermore, constituents of T. chinense including kaempferol-3-O-glucorhamnoside (KN, also named as Bairuisu I, 19), astragalin (AG, Bairuisu II, 12), and kaempferol (KF, Bairuisu III, 8), as well as CE and BG could alleviate lung inflammation caused by LPS in mice by preventing neutrophils infiltration and the expression of the genes for pro-inflammatory cytokines NLRP3, caspase-1, IL-1β, and COX-2. After a 28-day subacute toxicity test, BG at doses of 4.875 g/kg and 9.750 g/kg (equivalent to onefold and twofold the clinically recommended dose) and CE at a dose of 11.138 g/kg (equivalent to fourfold the clinical dose of BG) were found to be safe and non-toxic.
The discovery of sixty-three constituents comprehensively illustrated the material basis of T. chinense. T. chinense and Bairui Granules could alleviate lung inflammation by regulating inflammation-related proteins and no toxicity was observed under the twofold of clinically used doses.
百蕊草及其制剂(如百蕊颗粒)已被用于治疗炎症性疾病,如急性乳腺炎、大叶性肺炎、扁桃体炎、新型冠状病毒肺炎(COVID-19)和上呼吸道感染。然而,其物质基础、药理作用和安全性尚未阐明。
采用多种柱色谱法进行抗炎活性导向的成分分离,并通过核磁共振光谱和电子圆二色光谱计算阐明其结构。使用脂多糖(LPS)诱导的急性肺损伤(ALI)小鼠模型或正常小鼠,评估粗乙醇提取物(CE)、百蕊颗粒(BG)和纯化的活性成分对肺部炎症的抑制作用及安全性。
从百蕊草中分离出7个新化合物(1 - 7)和56个已知化合物(8 - 63),其中54个为首次从该植物中报道。新的黄酮苷1 - 2、新的脂肪酸4 - 5、新的生物碱7以及已知成分,包括黄酮苷元8 - 11、木脂素46 - 54、生物碱34和45、香豆素57、苯丙酸27以及简单芳香化合物39、44和58均表现出抗炎活性。网络药理学分析表明,百蕊草的抗炎作用归因于黄酮类和生物碱类成分对炎症相关蛋白(如TNF、NF-κB、TGF-β)的调节。此外,百蕊草的成分包括山柰酚-3-O-葡萄糖鼠李糖苷(KN,也称为百蕊素I,19)、紫云英苷(AG,百蕊素II,12)和山柰酚(KF,百蕊素III,8),以及CE和BG可通过阻止中性粒细胞浸润和促炎细胞因子NLRP3、caspase-1、IL-1β和COX-2基因的表达,减轻LPS诱导的小鼠肺部炎症。经过28天的亚急性毒性试验,发现剂量为4.875 g/kg和9.750 g/kg(相当于临床推荐剂量的1倍和2倍)的BG以及剂量为11.138 g/kg(相当于BG临床剂量的4倍)的CE是安全无毒的。
63种成分的发现全面阐明了百蕊草的物质基础。百蕊草和百蕊颗粒可通过调节炎症相关蛋白减轻肺部炎症,在临床使用剂量的2倍以下未观察到毒性。